Skip to content
DataLookout
Menu

CRP-SHOCKNCT07687017

CRP Apheresis in Infarct-Related Cardiogenic Shock

StatusRecruiting
PhaseNot applicable
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened Show 5 more changesShow less
    • Eligibility criteria shortened, about 7 words
    • Start date changed from estimate of Jul 20, 2026 to Oct 16, 2026
    • Secondary endpoints: details revised at 3 of 13 entries
    • Site details revised
    • Publications: details revised at 2 of 4 entries
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

CLIP score
Timeframe: 66 ± 8 hours after randomization

Secondary (13)

Major adverse cardiovascular events (MACE)
All-cause mortality
Cardiovascular mortality
CLIP score over time
Individual components of the CLIP score
Show 8 moreShow less
C-reactive protein (CRP) concentration
Peak NT-proBNP concentration
Peak serum creatinine concentration
Cardiac power index
Time to hemodynamic stabilization
Duration of catecholamine therapy
Length of intensive care unit stay
Length of hospital stay

Arms and interventions

Selective CRP Apheresis plus Standard of CareExperimental

Participants receive standard of care for infarct-related cardiogenic shock plus selective C-reactive protein (CRP) apheresis using the PentraSorb®-CRP system. CRP apheresis is initiated within 5 ± 1 hours after randomization and repeated at 30 ± 4 hours and 54 ± 6 hours after randomization.

Standard of CareActive comparator

Participants receive guideline-directed standard of care for infarct-related cardiogenic shock without CRP apheresis.

Devices: Selective C-reactive protein apheresis (PentraSorb®-CRP)

Other: Standard of care

Sites

1 site in 1 country

  • Heart Center Leipzig at University of LeipzigLeipzig, Saxony, Germany